WO2001031335A3 - Cell proliferation diagnosis and screening for modulators - Google Patents

Cell proliferation diagnosis and screening for modulators Download PDF

Info

Publication number
WO2001031335A3
WO2001031335A3 PCT/US2000/029570 US0029570W WO0131335A3 WO 2001031335 A3 WO2001031335 A3 WO 2001031335A3 US 0029570 W US0029570 W US 0029570W WO 0131335 A3 WO0131335 A3 WO 0131335A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
modulators
screening
cell proliferation
methods
Prior art date
Application number
PCT/US2000/029570
Other languages
French (fr)
Other versions
WO2001031335A2 (en
WO2001031335A9 (en
Inventor
Kenneth W Wood
Jeffrey T Finer
Christophe Beraud
John Mak
Roman Sakowicz
Original Assignee
Cytokinetics Inc
Kenneth W Wood
Jeffrey T Finer
Christophe Beraud
John Mak
Roman Sakowicz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Kenneth W Wood, Jeffrey T Finer, Christophe Beraud, John Mak, Roman Sakowicz filed Critical Cytokinetics Inc
Priority to DE60029812T priority Critical patent/DE60029812T2/en
Priority to EP00973914A priority patent/EP1224460B1/en
Priority to CA002387804A priority patent/CA2387804A1/en
Priority to AU12361/01A priority patent/AU1236101A/en
Publication of WO2001031335A2 publication Critical patent/WO2001031335A2/en
Publication of WO2001031335A3 publication Critical patent/WO2001031335A3/en
Publication of WO2001031335A9 publication Critical patent/WO2001031335A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Described herein are methods that can be used for diagnosis and prognosis of cellular proliferation. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate cellular proliferation. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in cancers are described.
PCT/US2000/029570 1999-10-27 2000-10-26 Cell proliferation diagnosis and screening for modulators WO2001031335A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE60029812T DE60029812T2 (en) 1999-10-27 2000-10-26 Diagnosis of cell proliferation and screening methods for their modulators
EP00973914A EP1224460B1 (en) 1999-10-27 2000-10-26 Cell proliferation diagnosis and screening for modulators
CA002387804A CA2387804A1 (en) 1999-10-27 2000-10-26 Methods of screening for modulators of cell proliferation and methods of diagnosing cell proliferation states
AU12361/01A AU1236101A (en) 1999-10-27 2000-10-26 Methods of screening for modulators of cell proliferation and methods of diagnosing cell proliferation states

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/428,156 US6617115B1 (en) 1999-10-27 1999-10-27 Methods of screening for modulators of cell proliferation
US09/428,156 1999-10-27

Publications (3)

Publication Number Publication Date
WO2001031335A2 WO2001031335A2 (en) 2001-05-03
WO2001031335A3 true WO2001031335A3 (en) 2001-11-01
WO2001031335A9 WO2001031335A9 (en) 2002-08-15

Family

ID=23697770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029570 WO2001031335A2 (en) 1999-10-27 2000-10-26 Cell proliferation diagnosis and screening for modulators

Country Status (8)

Country Link
US (5) US6617115B1 (en)
EP (2) EP1224460B1 (en)
AT (1) ATE335200T1 (en)
AU (1) AU1236101A (en)
CA (1) CA2387804A1 (en)
DE (1) DE60029812T2 (en)
ES (1) ES2269196T3 (en)
WO (1) WO2001031335A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60031285T2 (en) 1999-08-27 2007-08-30 Chemocentryx Inc., Mountain View HETEROCYCLIC COMPOUNDS AND METHOD FOR MODULATING CXCR3 FUNCTION
US6617115B1 (en) * 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6638754B1 (en) * 2000-11-28 2003-10-28 Cytokinetics, Inc. Motor proteins and methods for their use
EP1351671A1 (en) * 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
GB0108143D0 (en) * 2001-03-31 2001-05-23 Univ Dundee High-throughput screen
US9274101B2 (en) * 2001-04-20 2016-03-01 Biolog, Inc. Methods and kits for obtaining a metabolic profile of living animal cells
KR100915287B1 (en) * 2001-12-11 2009-09-03 교와 핫꼬 기린 가부시키가이샤 Thiadiazoline derivative
EP1551962A4 (en) * 2002-07-08 2007-08-01 Merck & Co Inc Mitotic kinesin binding site
US8032346B1 (en) 2002-08-28 2011-10-04 Rigel Pharmaceuticals, Inc. System and method for high-content oncology assay
US7970549B1 (en) 2002-08-28 2011-06-28 Rigel Pharmaceuticals Inc. System and method for high-content oncology assay
US20060110819A1 (en) * 2002-09-30 2006-05-25 Lomas Lee O Apparatus and method for expression and capture of biomolecules and complexes on adsorbent surfaces
WO2004035749A2 (en) * 2002-10-17 2004-04-29 Cytokinetics, Inc. MODIFIED NUCLEOTIDE SEQUENCE ENCODING C. ALBICANS Kip3 KINESIN PROTEIN
AU2004230799B2 (en) 2003-04-18 2010-03-18 Fujifilm Corporation Mitotic kinesin inhibitor
US20070134660A1 (en) * 2003-05-30 2007-06-14 Rosetta Inpharmatics Llc Methods for identifying modulators of kinesin activity
EP1632484A4 (en) * 2003-06-10 2008-09-03 Kyowa Hakko Kogyo Kk Thiadiazoline derivative
EP1677739A4 (en) * 2003-09-04 2008-07-23 Immusol Inc Methods of identifying agents that inhibit the growth of cancer cells
EP1670955A2 (en) * 2003-09-22 2006-06-21 Rosetta Inpharmatics LLC. Synthetic lethal screen using rna interference
EP1671957A4 (en) * 2003-10-10 2007-03-14 Thiadiazoline derivatives
JP2007514764A (en) * 2003-12-19 2007-06-07 スミスクライン・ビーチャム・コーポレイション Compounds, compositions and methods
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
JP4938451B2 (en) * 2004-03-23 2012-05-23 オンコセラピー・サイエンス株式会社 Methods for diagnosis of non-small cell lung cancer
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
AU2005247943A1 (en) * 2004-05-23 2005-12-08 Gerard M. Housey Theramutein modulators
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
TW200714593A (en) * 2005-03-22 2007-04-16 Kyowa Hakko Kogyo Kk Agent for treatment of solid tumor
CN101193877A (en) * 2005-03-22 2008-06-04 协和发酵工业株式会社 Agent for treatment of hematopoietic tumor
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd Therapeutic agent for restenosis
DE102006002065B4 (en) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Compensation component with reduced and adjustable on-resistance
EP2112509A1 (en) * 2008-03-25 2009-10-28 4Sc Ag Centrosome-assay
WO2011009523A1 (en) 2009-07-24 2011-01-27 Merck Patent Gmbh Eg5 as biomarker in rare thoracic cancer
EP2582682B1 (en) 2010-06-17 2015-01-14 Cytokinetics, Inc. Mitotic kinesin inhibitors for use in the treatmetnof pulmonary arterial hypertension

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018857A1 (en) * 1994-01-05 1995-07-13 Board Of Trustees Of The University Of Illinois Association of kinesin with sensitivity to chemotherapeutic drugs
WO1999034806A1 (en) * 1998-01-08 1999-07-15 The Regents Of The University Of California KINESIN MOTOR MODULATORS DERIVED FROM THE MARINE SPONGE $i(ADOCIA)
WO2000063353A1 (en) * 1999-04-20 2000-10-26 Cytokinetics Human kinesins and methods of producing and purifying human kinesins
WO2001007602A2 (en) * 1999-07-28 2001-02-01 Aventis Pharma Deutschland Gmbh Oligonucleotides for inhibiting the expression of human eg5

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007017A2 (en) 1998-07-27 2000-02-10 President And Fellows Of Harvard College Method of high-throughput screening
US6410254B1 (en) * 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6617115B1 (en) * 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018857A1 (en) * 1994-01-05 1995-07-13 Board Of Trustees Of The University Of Illinois Association of kinesin with sensitivity to chemotherapeutic drugs
WO1999034806A1 (en) * 1998-01-08 1999-07-15 The Regents Of The University Of California KINESIN MOTOR MODULATORS DERIVED FROM THE MARINE SPONGE $i(ADOCIA)
WO2000063353A1 (en) * 1999-04-20 2000-10-26 Cytokinetics Human kinesins and methods of producing and purifying human kinesins
WO2001007602A2 (en) * 1999-07-28 2001-02-01 Aventis Pharma Deutschland Gmbh Oligonucleotides for inhibiting the expression of human eg5

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOPKINS SETH C ET AL: "Inhibitors of kinesin activity from structure-based computer screening.", BIOCHEMISTRY, vol. 39, no. 10, 14 March 2000 (2000-03-14), pages 2805 - 2814, XP002166154, ISSN: 0006-2960 *
KAISER ASTRID ET AL: "All-trans-retinoic acid-mediated growth inhibition involves inhibition of human kinesin-related protein HsEg5.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 27, 2 July 1999 (1999-07-02), pages 18925 - 18931, XP002166152, ISSN: 0021-9258 *
MAYER THOMAS U ET AL: "Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen.", SCIENCE (WASHINGTON D C), vol. 286, no. 5441, 29 October 1999 (1999-10-29), pages 971 - 974, XP002166153, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
EP1224460A2 (en) 2002-07-24
EP1726954A2 (en) 2006-11-29
WO2001031335A2 (en) 2001-05-03
ES2269196T3 (en) 2007-04-01
AU1236101A (en) 2001-05-08
EP1224460B1 (en) 2006-08-02
DE60029812D1 (en) 2006-09-14
ATE335200T1 (en) 2006-08-15
US6437115B1 (en) 2002-08-20
US20040214249A1 (en) 2004-10-28
DE60029812T2 (en) 2007-03-29
CA2387804A1 (en) 2001-05-03
WO2001031335A9 (en) 2002-08-15
US6414121B1 (en) 2002-07-02
US20100261160A1 (en) 2010-10-14
US6617115B1 (en) 2003-09-09
EP1726954A3 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
WO2001031335A3 (en) Cell proliferation diagnosis and screening for modulators
WO2000055633A3 (en) Methods of screening for colorectal cancer modulators
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
WO2002021996A3 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
WO2001011086A3 (en) Methods of screening for angiogenesis modulators
ATE413386T1 (en) PPAR-GAMMA MODULATORS
PL336941A1 (en) Method of producing viral vectors not belonging to the group c
NZ516455A (en) Compounds for the modulation of PPARgamma activity
DK0667912T3 (en) Defective adenovirus vectors and their use in gene therapy
WO2002099054A3 (en) Hccss as modifiers of the p53 pathway and methods of use
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
WO2002055988A3 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
NZ334034A (en) Use of a melanoma differentiation associated gene (mda-7) for reversing a cancerous phenotype
AU2707797A (en) Methods and means for inhibition of cdk4 activity
ZA976697B (en) Amines for the manufacture of medicinal products intended to prevent the proliferation of tumour cells.
WO2002098889A3 (en) MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
MXPA04001720A (en) Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY.
WO2002016939A3 (en) Methods of diagnosis of cancer and screening for cancer modulators
WO2003035833A3 (en) Modifier of the p53 pathway and methods of use
WO2004075839A3 (en) Methods and compositions for modulating apoptosis
WO2003045321A3 (en) MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
WO2002059609A3 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2002021134A3 (en) Methods of diagnosing breast cancer and screening for modulators
WO2004038371A3 (en) Ccr8 as modifier of branching morphogenesis and methods of use
WO2004041076A3 (en) Methods of detecting colorectal cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2387804

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000973914

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000973914

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2000973914

Country of ref document: EP